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Diagnosis, Management, and Pathogenetic Studies in Medullary
Thyroid Carcinoma Syndrome
Naguib A. Samaan,* Kuo-Pao Paul Yang,* Pamela Schultz,* and R.C. Hickey*

A retrospective study of 224 patients with medullary thyroid carcinoma (MTC) diagnosed between
1963 and 1988 was performed lo 1) establish the diagnosis ofMTC in early childhood, 2) establish the
role of prophylactic regional lymphadenectomy in patients wilh MTC, 3) sludy the effect of
chemotherapy on MTC patients with metastatic disease, 4) sludy the effect of somatostatin analog
201-995 (Sandoz Pharmaceuticals) on the frequency of diarrhea in MTC, and 5) locate the common
region(s) of gene deletion on chromosome 1 and examine the loss of heterozygosity on chromosome 10
in tumors. Our data indicated that a progressive rise of serum calcitonin in early childhood (raiher
than the expectedfall with age seen in normal subjects) is diagnostic ofMTC. No differences in clinical
course or prognosis were observed between patients wilh MTC localized lo the thyroid who had
prophylactic neck node dissection and those who did not. Conventional chemotherapy had no
significant benefit in the treatment of patients with metastatic disease. The somatostatin analog was
found lo be an effeciive drug in the treatment of diarrhea associated with MTC. Allelic losses were
frequently found in MTCs and pheochromocytomas, and the loss of DNA sequences in these tumors
appeared to involve the distal third oflhe .short arm of chromosome 1, with a common breakpoint at
lp32. (Henry Ford Hosp MedJ 1989:37:132-7)

O

ver the last two decades much progress has been made in
our understanding of the medullary thyroid carcinoma
(MTC), both the hereditary and sporadic forms. However, many
questions remain unanswered. This study addresses the fotlowing five areas;
1. We showed in 1973 (1,2) that seram calcitonin (CT) is elevated at birth (Figs 1 and 2) and gradually decreases over time
(3), and we proposed that high CT during intrauterine fetal life
may be important for bone devetopment. These findings have
been confirmed by others (4,5). The quesfion raised by these observations is how to establish the diagnosis of MTC at an early
age when CT is physiologically elevated.
2. Another important question is how much nodal dissection,
if any, is needed when the disease is localized to the thyroid
gland.
3. Although we have shown that " ' I therapy for ablation therapy of MTC is ineffective (6) and that radiotherapy postoperatively is not beneficial (7), the role of various chemotherapeutic agents in advanced disease has not been thoroughly
discussed because the number of patients reported in the literature is too smalt to reach a significant conclusion.
4. A disabling dianhea can be the presenting manifestafion in
30% of patients with MTC (8). However, various drugs have
been used without success. We examined the possible benefits
of the somatostatin (SMS) analog 201-995 (Sandoz Pharmaceuficals) in MTC patients.
5. We tested the hypothesis of suppressor gene inactivation in
MTC and searched for the common region(s) of gene deletion on
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chromosome 1 and examined tumors also for toss of heterozygosity for chromosome 10.

Diagnosis of MTC at an Early Age
An infant was bom with skeletal deformities in the form of
clubbed feet and gastrointestinal signs of partial obstmction. A
biopsy from the rectum showed neuromata similar to that seen in
multiple endocrine neoplasia type 2B (MEN 2B), but the tips,
tongue, and eyelids showed no neuromata. There was no family
history of MTC or thyroid disease. Eye examination showed
thickening of the comeat nerves. MTC was suspected, but the
thyroid gland was clinically normal. Semm CT was measured
basally and after pentagastrin .stimulation (Nichols Laboratory,
San Juan Capistrano, CA). The basal CT level was 84 pg/mL
with a peak of 200 pg/mL two minutes after intravenous administration of pentagastrin, which was considered to be within the
normal range for infants of that age in that laboratory. Since we
have observed previously in our laboratory that seram CT is high
at birth and decreases with age in nonnal children, we elected to
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Fig 1—Serum calcitonin levels in different age groups showing
progressive decrease with age. (From Samaan NA, Anderson
CD, Adam-Mayne ME. Immunoreactive calcitonin in the
mother, neonate, child, and adult. Am J Obstet Gynecol
1975:121:622-5. Reprinted with permission.)
wait six months and repeat the pentagastrin stimulation test, parficularly since the infant was marasmic due to difficulties in
feeding.
At the age of 14 months, seram CT was again measured during pentagastrin stimulation in the same laboratory. The CT
level showed an increase both at basal and after pentagastrin
stimulation, which is contrary to what we observed in normal
subjects with progress of age (3). The basal CT level was 107 pg/
mL with a peak of 312 at 2 minutes. Total thyroidectomy revealed marked nodular C-cetl hyperplasia in the isthmus region.
CT was again measured 16 months foltowing surgery and the
basal levet was 14 pg/mL with noriseafter stimulation with pentagastrin. The patient is cunently in good heatth on thyroid
replacement.

MTC Localized to the Thyroid Gland:
Indications for Nodal Dissection
In the 224 patients diagnosed with MTC at The University of
Texas M.D. Anderson Cancer Center from 1944 to 1988, the
mean ± standard deviation of age at diagnosis was 43.0 ± 15.1
years. The males comprise 46% of the population. Totat thyroidectomy had been performed in 75% of the patients. At the
time of diagnosis the disease involved the thyroid gland and regional lymph nodes in 36% and the thyroid gland alone in 35%.
Extemal radiotherapy as an initial treatment had been performed
in 28% and radioactive iodine has been given to 10% of the patients. MEN 2 had been identified in 24% of the patients. Local
recunence in the neck had occurred in 30% and distant metastases have been documented in 37% of the patients. A total of 33%
had died of MTC (Table I). To determine if prophylactic neck
dissection was beneficial to the patients' outcome, those patients
who presented with disease to the thyroid gland onty and who
had neck dissection with negative lymph nodes (15 patients)
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Fig 2—Serum calcium (Ca), parathyroid hormone (PTH), and
calcitonin (CT) in nonpregnant, maternal, and cord blood.
Cord blood showed high serum calcium and CT and low PTH,
whereas maternal blood showed subnormal calcium levels and
high PTH and CT. (From Samaan NA, Wigoda C, Castillo SG.
Human serum calcitonin and parathyroid hormone levels in the
maternal, umbilical cord blood and postpartum. In: Endocrinology 1973. Proceedings of the Fourth International Symposium. London: William Heinemann Medical Books, Ltd,
1974:368. Reprinted with permission.)
Table 1
Population Characteristics of MTC Patients at The
University of M.D. Anderson Cancer Center (1944-1988)
and Localization of MTC at Presentation
Population Characteristics

Males: 103 (46%)
Mean Age (years)
± SD:45.5 ± 15.4
Females: 121 (54%)
Mean Age (years)
± SD: 40.8 ± 14.6
Hereditary Cases: 24%

Localization of MTC at Presentation

Thyroid gland:
Thyroid gland and nodes:
Thyroid gland, nodes, and soft
tissue:
Thyroid gland, nodes.
soft tissue, and
distant metastasis:

79 (35%)
81 (36%)
42 (22%)

18 (7%)

were compared with those who had involvement of the thyroid
gland onty and no neck dissection performed (43 patients).
When these two groups of patients were analyzed according to
age, sex, surgery, radiotherapy, radioactive iodine, MEN 2 syndrome, recurrence, and survival, no differences between the
groups were found (Table 2),

Radioactive Iodine, Radiotherapy, and
Chemotherapy in the Treatment of MTC
To determine the value of adjunct '-^'I therapy in MTC, two
groups of patients with histologically proven MTC with localized disease to the thyroid gland only were studied. Group A
consisted of 11 patients (six men and five women) treated by surgery followed by an ablative dose of ' ^ ' I , and group B included
46 patients (20 men and 26 women) treated by surgery atone.
Patients in group A were followed for 1,5 to 14 years (median
follow-up 53 months), and those in group B were followed for
one to 27 years (median follow-up 75 months). We found no dif-
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Table 2
Effect of Node Dissection of MTC Patients with LocaUzed
Disease to the Thyroid (58 Patients)

Number of patients
Mean age (years) ± SD
Males
Females
Total thyroidectomy
< Total thyroidectomy
X-ray treatment
MEN 2
Recurrence
Died
Mean follow-up (years)

Node
dissection

No node
dissection

15
37.5 ± 15.6
4 (27%)
11 (73%)
12 (80%)
3 (20%)
none
6 (40%)
6 (40%)
1 (7%)
11.9 ± 5.2

43
39.4 ± 14.5
11 (26%)
32 (74%)
35 (81%)
8 (19%)
none
15 (35%)
9 (21%)*
6 (14%)*
6.9 ± 5.1

*P>0.1.

ference in the two groups in the rate of recunence, metastasis, or
survival (Fig 3). We atso saw no significant difference in the
levet of CT between the two groups (6).
We found that when patients who received radiotherapy were
matched for age, extent of disease, and surgery with patients
who had had no radiotherapy, the untreated group was found to
live significantty longer (7) (P < 0.05) (Fig 4).
Twenty-three patients with metastatic MTC were treated by
various chemotherapeutic agents and 45 observations were recorded (some of the patients received more than one regimen)
(Tabte 3). The drags used were adriamycin atone, adriamycin
plus cisplarin, MeCCNU, and VP-t6, as well as other miscellaneous drugs such as DTIC, vincristine, bleomycin, etc.
The resutts were disappointing. None of the patients had complete remission and few had partial or minor response. Comptete remission was defined as disappearance of all evidence of
tumor for at teast four weeks and the patient being free of atl
symptoms of cancer. Partial response was defined as 50% or
greater decrease in the products of the diameter of atl measured
lesions for at least four weeks without increase in the size of any
other lesions or appearance of new lesions. Minor response was
defined as a decrease in a measurable lesion which is too small
to qualify as a partial response, and failure indicated an increase
in tumor size of at teast 25% or appearance of new lesions (Table
3).

Effect of SMS 201-995 on Diarrhea of MTC
Two patients with severe dianhea were also studied. A 39year-old white mate who had MTC with lymph node and soft
tissue involvement had surgery followed by radiotherapy to the
neck. Over the last year he noticed severe diarrhea which increased up to 35 stools per day. His CT was markedly elevated
(> 500 ng/mL; normal; 0 to 1 ng/mL) and his carcinoembryonic
antigen (CEA) was atso etevated (76 ng/mL; normal; 0 to 6 ng/
mL). He was given various drags for dianhea including lomotil,
emodium, and paragoric with no significant beneficial effect.
He was then given SMS 201-995, IOO |xg subcutaneously twice
daily, and two drops of tincture of opium threefimesdaily. His
diarrhea decreased to 2 to 4 stools per day, and he gained 7.6 kg
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Fig 3—Actuarial survival curves of patients with localized disease in both groups, showing no therapeutic effect of'-^'I in survival ofpatients with MTC. (From Saad MF, Guido JJ, Samaan
NA. Radioactive iodine in the treatment of medullary carcinoma
of the thyroid. J Clin Endocrinol Metab 1983 ;57;I24;8. Reprinted with permission.)
(17 lb) over a three-month period. The CT remained elevated (>
500 ng/mL) as did the CEA (79 ng/mL).
The second patient was a young, white female with MTC with
metastases to the bone and skin. She had dianhea with 15 to 20
stools per day and had tost a considerable amount of weight. She
could not tolerate small amounts of food and felt nauseated and
frequently vomited after meats. She was treated with SMS
201-995, too |xg twice daily, and two drops of tincture of opium
three times daily. She was no longer nauseated, had a good appetite , and gained 8.tkg(t8tb)in three months. Her CT and CEA
tevels were etevated at 190 ng/mL and 587 ng/mL, respectivety,
before SMS 201-995 therapy and remained elevated at 220 ng/
mL and 603 ng/mL, respectivety, after three months of therapy.
Both pafients atso showed nonnal 5-hydroxyindoteacetic acid
(5HIAA) and seratonin before and after treatment with no
change during therapy. The second patient took the tincture of
opium less frequently and inegutarty without an increase in the
frequency of dianhea.

Molecular Analysis for Losses of DNA Sequences
on Chromosomes 10 and lp
Hsu et al (9) reported cytogenetic studies suggesting that
MEN 2 patients exhibit some degree of chromosome instability.
Hsu et at (10) atso showed that cultures of peripheral lymphocytes from patients with MEN 2 were more susceptible than normal individuats to mutagen-induced chromosomal breakage,
with the frequent involvement of chromosomes I and 4. The
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Table 3
Effects of Chemotherapy in Medullary Thyroid Carcinoma
in 23 Patients and 45 Observations
Agents
Adriamycin
Adriamycin -1- cisplatin
Me CC Nu
VP-16
Miscellaneous

Number
10
10
3
2
20

Complete Partial
Minimal
Response Response Response Failure
0
0
0
0
0

2
2
0
0
0

2
2
0
1
0

6
6
3
I
20

higher frequency of spontaneous and induced chromosome aberrations in these patients woutd conceivably increase the probability of acquiring mutations at the target gene(s). However, in
studies of 25 members of four MEN 2A families, Fenell et at
(tt) failed to find evidence favoring linkage between the MEN
2A mutation and genetic markers assigned to chromosomes 1
and 4,
Recent linkage studies (12,13) have assigned the predisposing
gene for MEN 2A to chromosome 10, Since this predisposing
mutation would most likely be expressed by toss of the homologous normal allele as suggested by Knudson in his two-hit
model for carcinogenesis (14), we tested the hypothesis that the
genetic etiology for MEN 2A is analogous to that for such childhood tumors as retinoblastoma and Wilms tumor. We examined
the genotypes in constitutive and tumor cells from patients with
MEN 2A at the interstitial retinol-binding protein (RBP3) locus
which has been shown to link to MEN 2A (12,13,15),
DNAs from eight patients with hereditary/sporadic MTC or
pheochromocytoma were examined for the loss of heterozygosity at the RBP3 locus by the Southern blot technique.
However, none of the eight patients' genotypes were heterozygous for the marker, and we were unable to assess whether or
not one of the parental alleles of this chromosome 10 gene is lost
in their tumors, Flejter et at (16) recentty reviewed high-resolufion chromosome preparations from 23 MEN 2 families and
found no apparent abnormalities invotving chromosome 10,
Landsvater et at (17) and Nelkin et at (18) reported that the incidence of reduction to homozygosity for chromosome 10 DNA
markers in tumor DNA from MEN 2 patients was uncommon.
Nevertheless, the possibility remains that submicroscopic deletion or point mutation may exist in the chromosome 10 loci in
these tumor DNAs and may have escaped detection by these
studies. Therefore, the nature of mechanisms invotving chromosomes to in MEN 2 which resutt in the second mutational
event remains unclear,
Mathew et al (19) reported that toss of heterozygosity on chromosome tp was detectable in seven of 14 informative patients
with MTC or pheochromocytoma from both hereditary and sporadic cases. Simitar mutations at chromosome tp were atso
frequently detectable in neuroblastomas (20), a tumor which is
derived from the same embryonic origin as MEN 2. In other
types of tumors such as colorectal tumors and small cett carcinomas of the lung, multiple mutations invotving different
chromosomes have been implicated as the genetic mechanisms
for tumor initiation and progression (21-23). In tight of these
findings, we performed molecular anatysis aimed at determin-
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Fig 4—Comparison of survival in MTC patients matched for
age, extent of disease, and surgery. External radiation showed
no benefit, and those who received radiotherapy had shorter
survival than those who did not. (From Samaan NA, Schultz PN,
Hickey RC. Medullary thyroid carcinoma; Prognosis of familial
versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 1988;67;801-5. Reprinted with permission.)

ing the region on chromosome tp that may represent a common
deletion in MEN 2A in order to locate the potential tumor suppressor gene whose mutation is invotved in the processes of
tumorigenesis.
Five polymorphic DNA probes (PND,FUCAt, D1S57, Lmyc, and NGFB) that detect various chromosome tp loci plus a
tq marker (AT3) were used to examine allelic deletions for chromosome 1. Among the eight patients, allelic deletion at the Lmyc locus was clearly demonstrated by the loss of heterozygosity in two patients (Fig 5, cases 3 and 5) and by the reduction of about 50% of the gene copies in another two patients (Fig
5, cases 2 and 4) whose constitutional alleles were homozygous
at this locus. In the remaining four patients, whose constitutional DNAs were homozygous to this marker, the status of gene
deletion/inactivation at this locus could not be assessed. Patient
2's tumor DNA atso had multiple deletions at four loci between
tp32 and lp36, suggesting deletion of the distal third of tp. Tumor DNAs from four patients (cases 3,4,5, and 6) tost heterozygosity at one or two loci within the distal third of tp, suggesting interstitial deletions. Tumor DNA from patient 1 showed
abnormal band pattems in regions of DtS57 and FUCAl loci,
suggesting gene reanangement in the distal third of lp of this
tumor. The common region of gene deletion on chromosome tp
in these eight MEN 2A-associated tumors was determined to be
lp32 (Fig 6),

Discussion
We have previousty shown that CT is etevated in infants at
birth as wett as in the pregnant mother. We suggested that the
high CT in the presence of high serum calcium during intrauterine fetal life may play a rote in the bone formation of the
fetus. We atso suggested that the high CT in the mother may play
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Fig 5—Allelic deletion (patients 2, 3,4, and 5) at locus Ip32 in
eight cases of MTC and pheochromocytoma. DNAs were digested with EoRI. Upper panel: Southern hybridization patterns
ofthe 32p-labeled L-myc probe to DNAs from peripheral blood
leukocytes (L) and tumor cells (T)from each patient. Patient
numbers are indicated below the blots. Numbers to the right of
autoradiographs indicate the molecular size ofthe two polymorphic alleles in kilobases. Lower panel; Densitometric scans
of Southern hybridizations with 32P-labeled L-myc probe in
cells from patients 2 and 4. Solid lines represent the readings for
leukocyte DNA, and dotted lines represent those for tumor DNA.
A ^-globin gene probe serves as a control for normalization of
the hybridization intensity.

Fig 6—A summary ofthe allelic deletion on chromosome Ip in
the eight cases of MTC and pheochromocytomas studied. Open
boxes represent regions where patients' leukocyte DNA was heterozygous and tumor DNA showed loss of an allele; boxes with
vertical lines represent areas where patients' leukocyte DNA
was homozygous and tumor DNA showed an approximately
50% reduction in band intensity; solid boxes represent areas
where constitutional heterozygosity was retained in the tumors;
boxes with unidirectional diagonal lines represent regions
where patients' leukocyte DNA was homozygous and therefore
allelic deletion could not be assessed; boxes with crossed diagonal lines represent regions where patients' tumor DNA revealed
abnormal or new restriction fragments. The solid lines represent areas that we have not yet examined.

a rote in inhibiting the bone resorption in the presence of high
matemal parathyroid hormone which increases the absorption of
seram calcium from the gastrointestinal tract and reabsorption
ofthe calcium from the renal tubules, and thus calcium will be
available to the fetus (1,2). We have also shown that CT levels
decrease with age (3). These observations were confirmed by
others (4,5). However, the presence of elevated CT levels in
childhood presents major problems for diagnosis of MTC early
in life. We propose that if MTC or C-cell hyperplasia is suspected in early life, such as in our described patient, or in other
MEN 2 family members, the measurement of CT at various intervals in early life and the finding of the progressive rise in CT
rather than the expected fall may provide a diagnosis. This proposifion is confirmed in the patient described.
The extent of surgery which is indicated in the treatment of
MTC localized to the thyroid gland has been controversial
(24-26). Our data suggest that ifthe lymph node sampling shows
the middle compartment of the neck to be free of disease, no
lymph node dissection is necessary. We suggest that other centers should examine theirfindingsin this regard.
We previously reported that radioactive ablation for patients
with MTC failed to affect the remission or survival rate (6). We
also reported that when patients who received radiotherapy after
surgery for MTC were matched for age, extent of disease, and

surgery with patients who had no radiotherapy, the untreated
group was found to live significantly longer (7). We also showed
that adriamycin, cisplatin, and bleomycin had little tumoricidal
effects when administered as a single agent to cultured human
MTC cells (27,28). Our present findings also indicate that the
chemotherapy (such as adriamycin alone or in combination with
cisplatin or other drags such as bleomycin, vincristine, 5-fluorouracil, and methotrexate) has no measurable beneficial effect.
Diarrhea in MTC may be the presenting symptom in 30% of
patients (8) andean be disabling. Our results in two patients suggest that SMS 201-995 either alone or with tincture of opium is
effective in the treatment of diarrhea of MTC. The mechanism of
action is unclear since there was no significant change in the CT
level before and after treatment as well as no change in CEA,
serofinin, or the 24-hour urinary 5HIAA. The somatostatin analog may act on the peripheral tissue or through an inhibition of a
hormone, the nature of which is unknown.
The present study on pathogenetic mechanisms in MEN 2A
suggests that a tumor suppressor gene for MTC and pheochromocytoma might be located at the distal third of lp (most
likely at lp32) where mutant alleles seem to be involved in the
initiation and/or progression of these tumors. However, in view
ofthe evidence reported by others (21-23) suggesting that several tumor suppressor genes on different chromosomes may be
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invotved in suppressing the malignant phenotype in simitar but
distinct tumor types, it is possible that heterozygosity might be
tost frequently at other chromosomal loci atso.
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